Page 54 - TD-3-4

Tumor Discovery PPAR agonist and cancer

doi: 10.3322/caac.21559 doi: 10.3390/pharmaceutics15020504
4. Wang ZB, Liu D, Lei G, Liu ZQ, Wu N, Wang J. Ovarian 15. Li B, Jiang HY, Wang ZH, Ma YC, Bao YN, Jin Y. Effect of
cancer-targeted medication: PARP inhibitors, anti- fenofibrate on proliferation of SMMC-7721 cells via regulating
angiogenic drugs, immunotherapy, and more. Front cell cycle. Hum Exp Toxicol. 2021;40(7):1208-1221.
Pharmacol. 2023;14:1222209.
doi: 10.1177/0960327121991901
doi: 10.3389/fphar.2023.1222209
16. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer
5. Padma VV. An overview of targeted cancer therapy. statistics 2009. CA Cancer J Clin. 2009;59(4):225-249.
Biomedicine (Taipei). 2015;5(4):19.
doi: 10.3322/caac.20006
doi: 10.7603/s40681-015-0019-4
17. Gunthert AR, Grundker C, Hollmann K, Emons G.
6. Lim ZF, Ma PC. Emerging insights of tumor heterogeneity Luteinizing hormone-releasing hormone induces JunD-
and drug resistance mechanisms in lung cancer targeted DNA binding and extends cell cycle in human ovarian
therapy. J Hematol Oncol. 2019;12(1):134. cancer cells. Biochem Biophys Res Commun. 2002;294:11-15.
doi: 10.1186/s13045-019-0818-2 doi: 10.1016/S0006-291X(02)00427-8
7. Emran TB, Shahriar A, Mahmud AR, et al. Multidrug 18. Gründker C, Emons G. The role of gonadotropin-releasing
resistance in cancer: Understanding molecular mechanisms, hormone in cancer cell proliferation and metastasis. Front
immunoprevention and therapeutic approaches. Front Endocrinol (Lausanne). 2017;8:187.
Oncol. 2022;12:891652.
doi: 10.3389/fendo.2017.00187
doi: 10.3389/fonc.2022.891652
19. Kara M, Ozcagli E, Fragkiadaki P, et al. Determination of
8. Safri F, Nguyen R, Zerehpooshnesfchi S, George J, DNA damage and telomerase activity in stanozolol-treated
Qiao L. Heterogeneity of hepatocellular carcinoma: From rats. Exp Ther Med. 2017;13(2):614-618.
mechanisms to clinical implications. Cancer Gene Ther.
2024;31:1105-1112. doi: 10.3892/etm.2016.3974
doi: 10.1038/s41417-024-00764-w 20. George A, McLachlan J, Tunariu N, et al. The role of
hormonal therapy in patients with relapsed high-grade
9. Jackson C, Finikarides L, Freeman ALJ. The adverse effects ovarian carcinoma: A retrospective series of tamoxifen and
of trastuzumab-containing regimes as a therapy in breast letrozole. BMC Cancer. 2017;17(1):456.
cancer: A piggy-back systematic review and meta-analysis.
PLoS One. 2022;17(12):e0275321. doi: 10.1186/s12885-017-3440-0
doi: 10.1371/journal.pone.0275321 21. Joseph JD, Lu N, Qian J, et al. A clinically relevant androgen
receptor mutation confers resistance to second-generation
10. Shuel SL. Targeted cancer therapies: Clinical pearls for
primary care. Can Fam Physician. 2022;68(7):515-518. antiandrogens enzalutamide and ARN-509. Cancer Discov.
2013;3(9):1020-1029.
doi: 10.46747/cfp.6807515
doi: 10.1158/2159-8290.CD-13-0226
11. Levinson K, Dorigo O, Rubin K, Moore K. Immunotherapy
in gynecologic cancers: What we know now and where we 22. Korpal M, Korn JM, Gao X, et al. An F876L mutation
are headed. Am Soc Clin Oncol Educ Book. 2019;39:126-140. in androgen receptor confers genetic and phenotypic
resistance to MDV3100 (enzalutamide). Cancer Discov.
doi: 10.1200/EDBK_237967 2013;3(9):1030-1043.
12. Lobenwein D, Kocher F, Dobner S, Gollmann- doi: 10.1158/2159-8290.CD-13-0142
Tepeköylü C, Holfeld J. Cardiotoxic mechanisms of cancer
immunotherapy - A systematic review. Int J Cardiol. 23. Balbas MD, Evans MJ, Hosfield DJ, et al. Overcoming
2021;323:179-187. mutation-based resistance to antiandrogens with rational
drug design. Elife. 2013;2:e00499.
doi: 10.1016/j.ijcard.2020.08.033
doi: 10.7554/eLife.00499
13. Palaia I, Tomao F, Sassu CM, Musacchio L, Benedetti Panici
P. immunotherapy for ovarian cancer: Recent advances and 24. Feng LX, Li M, Liu YJ, Yang SM, Zhang N. Synergistic
combination therapeutic approaches. Onco Targets Ther. enhancement of cancer therapy using a combination of
2020;13:6109-6129. ceramide and docetaxel. Int J Mol Sci. 2014;15(3):4201-4220.
doi: 10.2147/OTT.S205950 doi: 10.3390/ijms15034201
14. Muthukutty P, Woo HY, Ragothaman M, Yoo SY. Recent 25. Duarte D, Vale N. Evaluation of synergism in drug
advances in cancer immunotherapy delivery modalities. combinations and reference models for future orientations in
Pharmaceutics. 2023;15(2):504. oncology. Curr Res Pharmacol Drug Discov. 2022;3:100110.

Volume 3 Issue 4 (2024) 11 doi: 10.36922/td.4003